Decoy Therapeutics Partners with hVIVO to Advance D-MAV into Phase 1 and 2a Trials
DCOY•Decoy Therapeutics has engaged hVIVO to support translational modeling, regulatory strategy and preparation for Phase 1 and Phase 2a human proof-of-concept trials of its lead Designable Multi-Antiviral (D-MAV) candidate. The collaboration leverages Decoy’s AI-enabled IMP³ACT platform on Google Cloud to enable rapid peptide antiviral development targeting multiple respiratory viruses.
1. Collaboration with hVIVO
Decoy Therapeutics has entered a strategic development partnership with hVIVO to support translational modeling, regulatory strategy and clinical development planning for its lead D-MAV candidate. hVIVO will assist with Phase 1 first-in-human and Phase 2a proof-of-concept study preparations, including CMC consulting and non-clinical development support.
2. Regulatory and Clinical Pathway
Under the agreement, hVIVO will prepare key regulatory documentation for IND and CTA submissions to the FDA, EMA and MHRA. This includes scientific advice preparation, challenge study design considerations and early human dose selection for respiratory antiviral programs.
3. AI-Driven Antiviral Platform
Decoy’s proprietary IMP³ACT platform combines AI-enabled peptide design on Google Cloud with rapid synthesis to create adaptable antivirals targeting shared mechanisms across multiple respiratory viruses. The collaboration output is intended to serve as a template for future D-MAV candidates, accelerating clinical timelines.
